AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:		APCBSSE/0091
Drug name and formulations:		Lisdexamfetamine capsules
Criteria	***Example***	**Committee Consensus**
Patient Safety	*Potential for abuse, toxicity, significant drug interactions*	Theoretically less abusable than other ADHD drugs
Clinical effectiveness	*Established licensed product*	Equal to or superior to other agents
Strength of evidence		Consistent evidence across all studies
Patient factors	*Published patient factors*	Once daily dosing schedule
Cost effectiveness or resource impact	*£*	Cost neutral
Place of therapy relative to available treatments	*1/2nd tier*	Lisdexamfetamine or methylphenidate 1st line in adults. lisdexamfetamine 2nd line in children over 5 years
National guidance and priorities	*NICE, MTRAC*	NICE guideline 72: Diagnosis and management of ADHD in children, young people and adults
Local health priorities	*CCG views*	As per other ADHD agents
Equity of access	*Equality assessment*	As per other ADHD agents
Stakeholder views	*Define wider groups to be engaged*	Supportive as per other ADHD agents – subject to commissioning discussions underway
Implementation requirements	*Requires, RICAD ESCA etc.*	ESCA

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	AMBER with ESCA (to be developed). Please note that commissioning discussion is underway and arrangements currently vary across BSSE area.
Implementation requirements:	ESCA

Implementation monitoring:	